ODI Pharma AB (publ) (NGM:ODI)
Sweden · Delayed Price · Currency is SEK 1.620
+0.100 (6.58%)
At close: Aug 11, 2025
ODI Pharma AB Revenue
ODI Pharma AB had revenue of 2.93M SEK in the quarter ending March 31, 2025, a decrease of -78.82%. This brings the company's revenue in the last twelve months to 10.57M, down -28.58% year-over-year. In the fiscal year ending June 30, 2024, ODI Pharma AB had annual revenue of 22.29M with 15,880.34% growth.
Revenue (ttm)
10.57M
Revenue Growth
-28.58%
P/S Ratio
2.88
Revenue / Employee
10.57M
Employees
1
Market Cap
30.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 22.29M | 22.15M | 15,880.34% |
| Jun 30, 2023 | 139.46K | -173.48K | -55.44% |
| Jun 30, 2022 | 312.94K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | - | - | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Investor AB | 85.17B |
| Atlas Copco AB | 173.03B |
| AB Volvo | 500.08B |
| EQT AB | 30.08B |
| ASSA ABLOY AB | 152.95B |
| Skandinaviska Enskilda Banken AB | 78.55B |
| Swedbank AB | 72.19B |
| Sandvik AB | 121.46B |